Krishna Institute of Medical Sciences Ltd
Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.
- Market Cap ₹ 10,643 Cr.
- Current Price ₹ 1,330
- High / Low ₹ 1,669 / 1,113
- Stock P/E 34.0
- Book Value ₹ 196
- Dividend Yield 0.00 %
- ROCE 34.1 %
- ROE 29.7 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 59.4% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.9%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|
512 | 567 | 664 | 918 | 1,123 | 1,330 | 1,651 | 1,994 | |
403 | 450 | 593 | 833 | 872 | 953 | 1,126 | 1,440 | |
Operating Profit | 109 | 118 | 71 | 85 | 251 | 377 | 524 | 554 |
OPM % | 21% | 21% | 11% | 9% | 22% | 28% | 32% | 28% |
5 | 3 | 37 | 6 | 5 | 9 | 27 | 52 | |
Interest | 37 | 32 | 88 | 49 | 44 | 37 | 22 | 29 |
Depreciation | 36 | 35 | 40 | 56 | 71 | 70 | 73 | 112 |
Profit before tax | 41 | 53 | -20 | -15 | 141 | 279 | 457 | 464 |
Tax % | 32% | 37% | -126% | -223% | 18% | 26% | 25% | |
Net Profit | 28 | 33 | -46 | -49 | 115 | 205 | 344 | 350 |
EPS in Rs | 3.78 | 4.55 | -6.61 | -6.40 | 16.00 | 25.93 | 41.57 | 40.44 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 24% |
3 Years: | 22% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 59% |
3 Years: | 108% |
TTM: | 1% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -1% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 27% |
Last Year: | 30% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|
70 | 72 | 50 | 74 | 74 | 78 | 80 | 80 | |
Reserves | 193 | 255 | -209 | 466 | 523 | 786 | 1,307 | 1,486 |
256 | 280 | 753 | 336 | 369 | 316 | 257 | 477 | |
146 | 167 | 359 | 237 | 228 | 253 | 260 | 651 | |
Total Liabilities | 665 | 774 | 954 | 1,114 | 1,194 | 1,433 | 1,904 | 2,694 |
515 | 518 | 755 | 863 | 916 | 931 | 1,005 | 1,780 | |
CWIP | 2 | 64 | 0 | 0 | 2 | 9 | 21 | 126 |
Investments | 11 | 14 | 0 | 0 | 0 | 0 | 332 | 60 |
137 | 177 | 199 | 250 | 276 | 493 | 546 | 728 | |
Total Assets | 665 | 774 | 954 | 1,114 | 1,194 | 1,433 | 1,904 | 2,694 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|
95 | 82 | 106 | 134 | 202 | 356 | 324 | |
-41 | -100 | -64 | -110 | -125 | -354 | -412 | |
-65 | 24 | -39 | -27 | -44 | 10 | 61 | |
Net Cash Flow | -11 | 5 | 3 | -3 | 32 | 12 | -26 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|
Debtor Days | 47 | 59 | 59 | 49 | 43 | 30 | 28 |
Inventory Days | 36 | 43 | 46 | 47 | 44 | 30 | 37 |
Days Payable | 194 | 207 | 215 | 181 | 177 | 167 | 133 |
Cash Conversion Cycle | -111 | -105 | -110 | -85 | -91 | -106 | -67 |
Working Capital Days | 11 | 26 | -315 | -7 | -10 | -6 | 4 |
ROCE % | 15% | 11% | 5% | 20% | 30% | 34% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
21 Mar - Company is having an Investors call with Sundaram Mutual funds on the 21st of March, 2023
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 Mar - Company is having an Investors call with Duro Capital on the 13th of March, 2023.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 8 Mar
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
15 Feb - In Continuation to our letter dated 8th February 2023 the Company organized a conference call with the Investors/ Analysts on Friday, 10th February 2023 at …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15 Feb - Management of the Company will be meeting various Investors at a conference organized by IIFL Securities in Mumbai on the 16th of February, 2023.
Concalls
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
Regional Leadership
KIMS is one of the largest corporate healthcare groups in Andhra Pradesh (AP) and Telangana in terms of the number of patients treated and treatments offered. It provides multidisciplinary integrated healthcare services, with a focus on primary, secondary & tertiary care in tier 2-3 cities and primary, secondary, tertiary, and quaternary healthcare in tier 1 cities. [1]